Pricing Log in Create free account

Mineralys Therapeutics, Inc. (MLYS) vs Zenas BioPharma, Inc. (ZBIO)

Mineralys Therapeutics, Inc. and Zenas BioPharma, Inc. are both Biotechnology companies. Mineralys Therapeutics, Inc. and Zenas BioPharma, Inc. are of similar size ($1.9B and $1.8B). Across the 9 metrics below, Mineralys Therapeutics, Inc. leads on 8 and Zenas BioPharma, Inc. on 1.

Valuation

Metric MLYS ZBIO Biotechnology median
P/E n/m n/m 8.58
P/S n/m n/m 10.29
P/B 3.28 7.22 2.29
Price to free cash flow n/m n/m 21.93
EV/EBITDA n/m n/m 0.67
EV/Sales n/m n/m 9.89
Earnings yield (19.86%) (31.82%) (31.56%)
Free cash flow yield (7.68%) (12.67%) (23.42%)

Profitability

Metric MLYS ZBIO Biotechnology median
Gross margin — — 65.77%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (80.88%) (199.04%) (54.09%)
Return on assets (69.67%) (97.39%) (47.78%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric MLYS ZBIO Biotechnology median
Revenue growth (TTM) — — 5.83%
EPS growth (last fiscal year) 37.43% 29.04% 29.36%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric MLYS ZBIO Biotechnology median
Debt to equity 0.18 1.57 0.00
Current ratio 34.46 9.93 4.80
Net debt to EBITDA 3.85 0.69 0.97

Dividend

Metric MLYS ZBIO Biotechnology median
Dividend yield — — 0.44%
Payout ratio — — —

Size

Metric MLYS ZBIO Biotechnology median
Market cap 1.87b 1.83b 153.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack